Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipilimumab in a real‐world population: A prospective Phase
IV
trial with long‐term follow‐up
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-08-28
DOI
10.1002/ijc.33768
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive biomarkers for response to immune checkpoint inhibition
- (2021) Benjamin Shum et al. SEMINARS IN CANCER BIOLOGY
- C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
- (2020) Tatsuya Yoshida et al. Journal for ImmunoTherapy of Cancer
- Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
- (2020) Naoya Yamazaki et al. JOURNAL OF DERMATOLOGY
- Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
- (2020) Andressa S Laino et al. Journal for ImmunoTherapy of Cancer
- Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
- (2020) David M Favara et al. ESMO Open
- Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
- (2020) Sebastiano Buti et al. EUROPEAN JOURNAL OF CANCER
- Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
- (2020) Caroline Robert et al. EUROPEAN JOURNAL OF CANCER
- Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis
- (2020) Filippo Gustavo Dall'Olio et al. Immunotherapy
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors
- (2019) Wouter Ouwerkerk et al. MELANOMA RESEARCH
- Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
- (2019) M. Nyakas et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands
- (2018) Anouk Jochems et al. ANTI-CANCER DRUGS
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
- (2018) Kohei Fujita et al. RESPIRATORY MEDICINE
- Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study
- (2017) Alberto Russi et al. JOURNAL OF CHEMOTHERAPY
- Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab
- (2017) P. Mohr et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting
- (2016) Beatriz Guglieri-López et al. ANTI-CANCER DRUGS
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
- (2016) Maria Del Castillo et al. CLINICAL INFECTIOUS DISEASES
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Prognostic score for patients with advanced melanoma treated with ipilimumab
- (2015) Stefan Diem et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Ipilimumab in the real world
- (2015) Saif S. Ahmad et al. MELANOMA RESEARCH
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- Ipilimumab for advanced melanoma
- (2014) Alfonso Berrocal et al. MELANOMA RESEARCH
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now